Severe lupus nephritis: the predictive value of a ≥50% reduction in proteinuria at 6 months

被引:49
作者
Korbet, Stephen M. [1 ]
Lewis, Edmund J. [1 ]
机构
[1] Rush Univ, Dept Med, Nephrol Sect, Med Ctr, Chicago, IL 60612 USA
关键词
proteinuria; remission; severe lupus nephritis; TERM-FOLLOW-UP; LONG-TERM; MYCOPHENOLATE-MOFETIL; HISTOLOGIC PATTERNS; CYCLOPHOSPHAMIDE; CLASSIFICATION; REMISSION; THERAPY; GLOMERULONEPHRITIS; MANAGEMENT;
D O I
10.1093/ndt/gft201
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. A complete remission (CR) in severe lupus nephritis (SLN) is associated with a favorable long-term outcome. Initial therapy may be up to 6 months, but many patients do not achieve a CR until after 12 months. We assess the value of a >= 50% reduction in proteinuria (UPro) at 6 months in predicting the outcome in SLN patients. Methods. We evaluated the 86 adult patients in the prospective, controlled trial of plasmapheresis (PP) in SLN (NEJM 1992). Patients with a CR (n = 12), end-stage renal disease (ESRD) or death (n = 13) at <= 6 months were excluded. The remaining 61 patients were categorized into two groups based on having attained >= = 50% reduction in UPro at 6 months: (yes) 34 patients and (no) 27 patients. The long-term outcomes were compared. A CR was defined by a serum creatinine (SCr) of <= 1.4 mg/dL and UPro of <= 0.33 g/day. Results. Baseline features were similar, but the UPro was higher (7.1 +/- 3.6 versus 4.6 +/- 3.2, P 0.002) in the group with a >= 50% reduction in UPro at 6 months. At follow-up, a CR was attained in 56% of patients with >= = 50% reduction in UPro at 6 months compared with 22% (P = 0.009) in the group without. The 15-year renal survival (71 versus 25%, P = 0.005) and patient survival without ESRD (66 versus 18%, P = 0.004) was greatest in the patients with a >= 50% reduction in UPro at 6 months. Conclusion. A >= 50% reduction in UPro at 6 months predicts a favorable outcome in SLN.
引用
收藏
页码:2313 / 2318
页数:6
相关论文
共 33 条
[1]   LONG-TERM FOLLOW-UP OF PATIENTS WITH LUPUS NEPHRITIS - A STUDY BASED ON THE CLASSIFICATION OF THE WORLD-HEALTH-ORGANIZATION [J].
APPEL, GB ;
COHEN, DJ ;
PIRANI, CL ;
MELTZER, JI ;
ESTES, D .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (05) :877-885
[2]   Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis [J].
Appel, Gerald B. ;
Contreras, Gabriel ;
Dooley, Mary Anne ;
Ginzler, Ellen M. ;
Isenberg, David ;
Jayne, David ;
Li, Lei-Shi ;
Mysler, Eduardo ;
Sanchez-Guerrero, Jorge ;
Solomons, Neil ;
Wofsy, David .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (05) :1103-1112
[3]   Clinical presentation and monitoring of lupus nephritis [J].
Balow, JE .
LUPUS, 2005, 14 (01) :25-30
[4]   Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis [J].
Bertsias, George K. ;
Tektonidou, Maria ;
Amoura, Zahir ;
Aringer, Martin ;
Bajema, Ingeborg ;
Berden, Jo H. M. ;
Boletis, John ;
Cervera, Ricard ;
Doerner, Thomas ;
Doria, Andrea ;
Ferrario, Franco ;
Floege, Juergen ;
Houssiau, Frederic A. ;
Ioannidis, John P. A. ;
Isenberg, David A. ;
Kallenberg, Cees G. M. ;
Lightstone, Liz ;
Marks, Stephen D. ;
Martini, Alberto ;
Moroni, Gabriela ;
Neumann, Irmgard ;
Praga, Manuel ;
Schneider, Matthias ;
Starra, Argyre ;
Tesar, Vladimir ;
Vasconcelos, Carlos ;
van Vollenhoven, Ronald F. ;
Zakharova, Helena ;
Haubitz, Marion ;
Gordon, Caroline ;
Jayne, David ;
Boumpas, Dimitrios T. .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (11) :1771-1782
[5]   Outcome criteria for lupus nephritis trials: A critical overview [J].
Boumpas, DT ;
Balow, JE .
LUPUS, 1998, 7 (09) :622-629
[6]   Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis [J].
Chan, TM ;
Li, FK ;
Tang, CSO ;
Wong, RWS ;
Fang, GX ;
Ji, YL ;
Lau, CS ;
Wong, AKM ;
Tong, MKL ;
Chan, KW ;
Lai, KN .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (16) :1156-1162
[7]   Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine [J].
Chan, TM ;
Tse, KC ;
Tang, CSO ;
Lai, K ;
Li, FK .
LUPUS, 2005, 14 (04) :265-272
[8]   Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis [J].
Chan, TM ;
Tse, KC ;
Tang, CSO ;
Mok, MY ;
Li, FK .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (04) :1076-1084
[9]   Value of a complete or partial remission in severe lupus nephritis [J].
Chen, Yiann E. ;
Korbet, Stephen M. ;
Katz, Robert S. ;
Schwartz, Melvin M. ;
Lewis, Edmund J. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (01) :46-53
[10]  
CHURG J, 1995, RENAL DIS CLASSIFICA, P151